-
21.发明授权Method for producing a factor VIII/von Willebrand factor complex 有权生产因子VIII / von Willebrand因子复合物的方法公开(公告)号：US06605222B1
公开(公告)日：2003-08-12
申请号：US09623245
申请日：2001-03-19
IPC分类号： B01D1508
CPC分类号： C07K14/755 , A61K38/00
摘要： The invention relates to a method for the production of factor VIII:C/von Willebrand factor complex from plasma or a plasma fraction by chromatography in a cation exchanger, wherein the factor VIII:C/von Willebrand factor complex is obtained with at least 300 times the purity of the plasma and the yield of factor VIII:C and the von Willebrand factor is at least 50% in relation to cryoprecipitates or analogous plasma fractions.
摘要翻译： 本发明涉及一种在阳离子交换器中通过色谱法从血浆或血浆级分生成因子VIII：C / von Willebrand因子复合物的方法，其中获得因子VIII：C / von Willebrand因子复合物至少300次 相对于冷沉淀物或类似的血浆级分，血浆的纯度和因子VIII：C和血管性血友病因子的产率至少为50％。
-
22.发明授权Parenterally administrable drug having thrombolytic activity and containing protein C 失效具有溶栓活性并含有蛋白质C的可口服给药的药物
公开(公告)号：US5580962A
公开(公告)日：1996-12-03
申请号：US416533
申请日：1995-04-03
申请人： Johann Eibl , Yendra Linnau , Anton Philapitsch , Hans P. Schwarz
发明人： Johann Eibl , Yendra Linnau , Anton Philapitsch , Hans P. Schwarz
IPC分类号： A61K38/43 , A61K38/00 , A61K38/46 , A61K38/48 , A61K38/49 , A61K38/54 , A61K39/395 , A61K45/06 , A61P7/02 , C07K1/16 , C07K1/22 , C07K14/00 , C07K16/00 , C12N9/54 , C12N9/64 , C12N9/68 , C12N9/72 , C12N9/99 , C07K1/00
CPC分类号： C12N9/6435 , A61K38/49 , A61K45/06 , C12N9/6462 , C12N9/6464 , C12Y304/21007 , C12Y304/21069 , C12Y304/21073
摘要： A thrombolytic, parenterally administrable drug containing activated protein C is provided for. The drug is free of serum amyloid P, thrombin activity, infectious agents and antibodies against protein C and activated protein C.
摘要翻译： 提供了含有活化蛋白C的溶栓剂，肠胃外给药的药物。 该药物无血清淀粉样蛋白P，凝血酶活性，感染因子和抗蛋白C和活化蛋白C的抗体。
-
公开(公告)号：US5324628A
公开(公告)日：1994-06-28
申请号：US775587
申请日：1991-10-15
申请人： Yendra Linnau
发明人： Yendra Linnau
IPC分类号： A61K35/16 , A61K38/16 , A61K39/395 , C07K14/76 , C07K16/06 , C12P21/06 , C12N11/10 , C07K3/20 , C07K15/00 , C07K17/10
CPC分类号： A61K35/16 , C07K14/76 , C07K16/065 , C12P21/06 , Y10S530/831
摘要： In order to avoid the risk of undesired side reactions of blood products, the latter are produced from plasma by using chymotrypsin to inactivate prekallikrein activator. These preparations are obtained by the fractionated enrichment of plasma proteins, with the proviso that a chymotrypsin solution or immobilized chymotrypsin is added to the fractions at any stage of the fractionation process. Before completion of the preparations, the chymotrypsin or the immobilized trypsin is removed from the preparations.
摘要翻译： 为了避免血液制品不良反应的风险，后者是通过使用胰凝乳蛋白酶来灭活前激肽释放激素从血浆中产生的。 这些制剂通过血浆蛋白的分级富集获得，条件是在分级过程的任何阶段将糜蛋白酶溶液或固定的糜蛋白酶加入到级分中。 在制备完成之前，从制剂中除去胰凝乳蛋白酶或固定化的胰蛋白酶。
-
24.发明授权
公开(公告)号：US5094949A
公开(公告)日：1992-03-10
申请号：US315163
申请日：1989-02-24
申请人： Yendra Linnau
发明人： Yendra Linnau
CPC分类号： A61K35/16 , C07K14/76 , C07K16/065 , C12P21/06 , Y10S530/831
摘要： In order to avoid the risk of undesired side reactions of blood products, the latter are produced from plasma by using chymotrypsin to inactivate prekallikrein activator. These preparations are obtained by the fractionated enrichment of plasma proteins, with the proviso that a chymotrypsin solution or immobilized chymotrypsin is added to the fractions at any stage of the fractionation process. Before completion of the preparations, the chymotrypsin or the immobilized trypsin is removed from the preparations.
摘要翻译： 为了避免血液制品不良反应的风险，后者是通过使用胰凝乳蛋白酶来灭活前激肽释放激素从血浆中产生的。 这些制剂通过血浆蛋白的分级富集获得，条件是在分级过程的任何阶段将糜蛋白酶溶液或固定的糜蛋白酶加入到级分中。 在制备完成之前，从制剂中除去胰凝乳蛋白酶或固定化的胰蛋白酶。
-
25.发明授权Process for producing a plasma protein-containing medicament with reduced concentration of citrate and metals 有权用于生产具有降低的柠檬酸盐和金属浓度的含血浆蛋白的药物的方法公开(公告)号：US08709492B2
公开(公告)日：2014-04-29
申请号：US11151295
申请日：2005-06-14
申请人： Wolfgang Teschner , Yendra Linnau , Sonja Svatos , Herwig Igel
发明人： Wolfgang Teschner , Yendra Linnau , Sonja Svatos , Herwig Igel
IPC分类号： A61K35/16
CPC分类号： A61K35/16 , A61K38/1709 , C07K14/76 , C07K16/06
摘要： There is disclosed a method of preparing a plasma-protein-containing medicament from citrated plasma or from a citrate-containing plasma fraction, the medicament being substantially free from undesired metals, which method comprises the following steps: exchanging the citrate and optionally citrate-bound metals in a plasma-protein-containing solution for a water-soluble mono- or dicarboxylate or for an organic mono- or dicarboxylic acid under non-precipitating conditions, recovering the plasma protein or the plasma proteins, and finishing the medicament.
摘要翻译： 公开了一种从柠檬酸盐血浆或含柠檬酸盐血浆级分制备含血浆蛋白的药物的方法，该药物基本上不含不期望的金属，该方法包括以下步骤：将柠檬酸盐和任选的柠檬酸盐结合 用于水溶性单羧酸盐或二羧酸盐的含血浆蛋白的溶液中的金属或非沉淀条件下的有机单羧酸或二羧酸的金属，回收血浆蛋白或血浆蛋白，以及整理药物。
-
26.发明授权公开(公告)号：US06395880B1
公开(公告)日：2002-05-28
申请号：US09509052
申请日：2000-05-26
申请人： Yendra Linnau , Ernst Hetzl , H. Peter Matthiessen , Silvia Neppl , Wolfgang Schönhofer , Hans-Peter Schwarz
发明人： Yendra Linnau , Ernst Hetzl , H. Peter Matthiessen , Silvia Neppl , Wolfgang Schönhofer , Hans-Peter Schwarz
IPC分类号： C12N974
CPC分类号： C07K14/8128 , A61K38/00
摘要： A method of purifying antithrombin III (AT III) from a starting material containing an AT III/heparin complex or an AT III/heparinoid complex is disclosed. First, the method comprises adsorbing the AT III/heparin complex or the AT III/heparinoid complex on an anion exchanger material. Second, the method involves separating the AT III from the adsorbed AT III/heparin complex or an AT III/heparinoid complex by elution with a buffer having a pH ranging from 8.5 to 10.5 and a conductivity between 10 and 60 mS.
摘要翻译： 公开了从含有AT III /肝素复合物或AT III /类肝素复合物的原料中纯化抗凝血酶III（AT III）的方法。 首先，该方法包括在阴离子交换材料上吸附AT III /肝素复合物或AT III /类肝素复合物。 第二，该方法包括通过用pH为8.5至10.5和10至60mS的电导率的缓冲液洗脱来分离AT III与吸附的AT III /肝素复合物或AT III /类肝素复合物。
-
27.发明授权
公开(公告)号：US5864016A
公开(公告)日：1999-01-26
申请号：US281110
申请日：1994-07-28
申请人： Johann Eibl , Friedrich Elsinger , Yendra Linnau , Gunther Wober
发明人： Johann Eibl , Friedrich Elsinger , Yendra Linnau , Gunther Wober
CPC分类号： A61L2/0088 , A61L2/0023
摘要： A blood product, exclusive of albumin, inactivated relative to infectious agents, the blood product conforming to a total virus reduction factor of at least 40, having a biological acitity of at least 50%, based on its activity prior to effecting inactivation of the infectious agents, the blood product being producible from conventional blood products and being virus-safe.
摘要翻译： 相对于感染因子而言，不含白蛋白的血液产品灭活，符合至少40的总病毒减少因子的血液制品，其生物学活性至少为50％，基于其在感染性疾病失活之前的活性 药物，血液制品可从常规血液制品生产并且是病毒安全的。
-
28.发明授权
公开(公告)号：US5614405A
公开(公告)日：1997-03-25
申请号：US258367
申请日：1994-06-10
申请人： Johann Eibl , Friedrich Elsinger , Yendra Linnau , Gunther Wober
发明人： Johann Eibl , Friedrich Elsinger , Yendra Linnau , Gunther Wober
CPC分类号： A61L2/0088 , A61L2/0023
摘要： This invention is directed to a method of evaluating viral reduction capability of a viral inactivation step in a viral inactivation procedure. The method requires spiking a biological product with a virus more than once during the viral inactivation step so that a virus reduction factor can be calculated.
摘要翻译： 本发明涉及评估病毒灭活步骤中的病毒灭活步骤的病毒还原能力的方法。 该方法需要在病毒灭活步骤期间使具有病毒的生物产物超过一次，从而可以计算出病毒还原因子。
-
29.发明授权
公开(公告)号：US5608038A
公开(公告)日：1997-03-04
申请号：US359901
申请日：1994-12-20
申请人： Johann Eibl , Yendra Linnau , Wolfgang Teschner
发明人： Johann Eibl , Yendra Linnau , Wolfgang Teschner
CPC分类号： A61K9/0019 , A61K39/39591 , A61K47/02 , A61K47/26
摘要： A stable, highly concentrated intravenously tolerable immunoglobulin preparation is described having an immunoglobulin content from 13.5 to 17.5% (w/v), an osmolarity from 250 to 600 mOs/l and a viscosity of no more than 9 cP. The immunoglobulin preparation possesses an exceptional imperishability and also is used as a highly concentrated preparation without problems due to its low viscosity.
摘要翻译： 描述了稳定的，高度浓缩的静脉内可耐受的免疫球蛋白制剂，其免疫球蛋白含量为13.5至17.5％（w / v），摩尔渗透压浓度为250至600mOs / l，粘度不超过9cP。 免疫球蛋白制剂具有优异的不均匀性，并且由于其低粘度而被用作高度浓缩的制剂而没有问题。
-
30.发明授权Method of dissolving venous Thrombi using drug containing activated Protein C 失效使用含活化蛋白C的药物溶解静脉血栓的方法
公开(公告)号：US5478558A
公开(公告)日：1995-12-26
申请号：US430298
申请日：1995-04-28
申请人： Johann Eibl , Yendra Linnau , Anton Philapitsch , Hans P. Schwarz
发明人： Johann Eibl , Yendra Linnau , Anton Philapitsch , Hans P. Schwarz
IPC分类号： A61K38/43 , A61K38/00 , A61K38/46 , A61K38/48 , A61K38/49 , A61K38/54 , A61K39/395 , A61K45/06 , A61P7/02 , C07K1/16 , C07K1/22 , C07K14/00 , C07K16/00 , C12N9/54 , C12N9/64 , C12N9/68 , C12N9/72 , C12N9/99
CPC分类号： C12N9/6435 , A61K38/49 , A61K45/06 , C12N9/6462 , C12N9/6464 , C12Y304/21007 , C12Y304/21069 , C12Y304/21073
摘要： A method of dissolving venous thrombi using a thrombolytic, parenterally administrable drug containing activated protein C is described. The drug can be free of serum amyloid P, thrombin activity, infectious agents and antibodies against protein C and activated protein C.
摘要翻译： 描述了使用含有活化蛋白C的溶血栓，肠胃外给药的药物溶解静脉血栓的方法。 该药物可以不含血清淀粉样蛋白P，凝血酶活性，感染因子和抗蛋白C和活化蛋白C的抗体。
-
-
-
-
-
-
-
-
-
搜索结果
40 条记录 (耗时 0.02 秒)
